Barreiro Gabriela, Guimarães Cristiano R W, Tubert-Brohman Ivan, Lyons Theresa M, Tirado-Rives Julian, Jorgensen William L
Department of Chemistry, Yale University, 225 Prospect Street, New Haven, CT 06520-8107, USA.
J Chem Inf Model. 2007 Nov-Dec;47(6):2416-28. doi: 10.1021/ci700271z. Epub 2007 Oct 20.
A virtual screening protocol has been applied to seek non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) and its K103N mutant. First, a chemical similarity search on the Maybridge library was performed using known NNRTIs as reference structures. The top-ranked molecules obtained from this procedure plus 26 known NNRTIs were then docked into the binding sites of the wild-type reverse transcriptase (HIV-RT) and its K103N variant (K103N-RT) using Glide 3.5. The top-ranked 100 compounds from the docking for both proteins were post-scored with a procedure using molecular mechanics and continuum solvation (MM-GB/SA). The validity of the virtual screening protocol was supported by (i) testing of the MM-GB/SA procedure, (ii) agreement between predicted and crystallographic binding poses, (iii) recovery of known potent NNRTIs at the top of both rankings, and (iv) identification of top-scoring library compounds that are close in structure to recently reported NNRTI HTS hits. However, purchase and assaying of selected top-scoring compounds from the library failed to yield active anti-HIV agents. Nevertheless, the highest-ranked database compound, S10087, was pursued as containing a potentially viable core. Subsequent synthesis and assaying of S10087 analogues proposed by further computational analysis yielded anti-HIV agents with EC50 values as low as 310 nM. Thus, with the aid of computational tools, it was possible to evolve a false positive into a true active.
一种虚拟筛选方案已被应用于寻找HIV-1逆转录酶(非核苷类逆转录酶抑制剂)及其K103N突变体的非核苷类抑制剂。首先,以已知的非核苷类逆转录酶抑制剂作为参考结构,在Maybridge库上进行化学相似性搜索。然后,使用Glide 3.5将从该过程中获得的排名靠前的分子以及26种已知的非核苷类逆转录酶抑制剂对接至野生型逆转录酶(HIV-RT)及其K103N变体(K103N-RT)的结合位点。对两种蛋白质对接得到的排名靠前的100种化合物,使用分子力学和连续溶剂化(MM-GB/SA)程序进行后评分。虚拟筛选方案的有效性得到以下几点支持:(i)MM-GB/SA程序的测试;(ii)预测的结合姿势与晶体学结合姿势之间的一致性;(iii)在两个排名靠前的位置均回收了已知的强效非核苷类逆转录酶抑制剂;(iv)鉴定出在结构上与最近报道的非核苷类逆转录酶抑制剂高通量筛选命中物相近的得分最高的库化合物。然而,从库中购买并检测选定的得分最高的化合物未能产生有活性的抗HIV药物。尽管如此,排名最高的数据库化合物S10087因其含有潜在可行的核心结构而被继续研究。通过进一步的计算分析提出的S10087类似物的后续合成和检测产生了EC50值低至310 nM的抗HIV药物。因此,借助计算工具,有可能将假阳性转化为真正的活性物质。